体外诱导对氨基水杨酸高浓度耐药结核分枝杆菌及其突变位点研究

doi:10.19982/j.issn.1000-6621.20220457

摘要/Abstract

摘要：

目的: 通过对实验室诱导产生的对氨基水杨酸(para-aminosalicylic acid, PAS)耐药结核分枝杆菌(Mycobacterium tuberculosis,MTB)和临床分离株进行全基因组测序,探索PAS的潜在作用机制和耐药性。方法: 通过体外药物浓度梯度诱导法,将MTB标准菌株H37Rv诱导成标准耐PAS菌株及高水平耐药菌株,收集并保存每一代诱导菌株。用液体微孔板法检测上述诱导菌株的最低抑菌浓度(minimum inhibitory concentration,MIC)及交叉耐药情况,筛选耐药水平相似的临床分离株。通过对PAS耐药的实验室突变株和临床分离株进行全基因组测序,从基因水平上探索MTB对PAS的耐药机制。结果: 本研究在体外建立了耐PAS的MTB耐药动态变化模型。全基因组测序结果显示,PAS耐药可能与3个位点突变直接相关,分别是plcC (Q462R)、folC (S150R)和1个thyA上游位点(3074495G→A)。MTB对高水平的PAS耐药的产生除了基因突变因素以外,尚存在其他的调控机制。对PAS敏感和耐药的MTB临床分离株测序发现某些folC、thyA和thyX突变并非由PAS引起。结论: 本研究构建的PAS耐药MTB菌株模型,为PAS耐药结核病研究和临床实践提供了理想的生物模型。全基因组测序分析在DNA水平上阐明了MTB对PAS的耐药机制,尚存在其他的调控机制,仍需进一步研究。所得的与PAS耐药相关的基因突变也需要进一步的实验验证。

关键词: 分枝杆菌, 结核, 对氨基水杨酸, 抗药性, 细菌, 基因, 细菌, 突变

Abstract:

Objective: To explore the potential mechanisms of action and resistance to para-aminosalicylic acid (PAS) by sequencing the whole genome (WGS) of lab-induced PAS-resistant Mycobacterium tuberculosis (MTB) and clinical isolates. Methods: The MTB standard strain was induced into standard PAS resistant strain and high-level drug resistant strain by in vitro drug concentration gradient induction method, and the induced strains of each generation were collected and preserved. The minimum inhibitory concentration (MIC) and cross resistance of the above induced strains were detected by liquid microplate method, and clinical isolates with similar drug resistance levels were screened. By sequencing the whole genome of PAS resistant laboratory mutants and clinical isolates, the mechanism of resistance of MTB to PAS was explored at the gene level. Results: A dynamic PAS-resistant model of MTB was established in vitro. The WGS results showed that PAS resistance may be directly related to three site mutations, plcC (Q462R), folC (S150R) and a thyA upstream site (3074495G→A). Except for genetic mutations, there were other regulatory mechanisms for the resistance to high levels PAS of MTB. Moreover, WGS results of PAS-susceptible and resistant clinical isolates revealed that some folC, thyA and thyX mutations were not caused by PAS. Conclusion: The PAS-resistant model of MTB constructed in this study provides an ideal biological model for the research and clinical practice of PAS-resistant tuberculosis. WGS analysis has clarified the resistance mechanism of MTB to PAS at the DNA level, and other regulatory mechanisms still need further investigation. The gene mutations associated with PAS resistance obtained in this study also need further experimental validation.

Key words: Mycobacterium tuberculosis, Para-aminosalicylic acid, Drug resistance, bacterial, Genes, bacterial, Mutation

中图分类号:

R52
R453

余美玲, 张晨晨, 魏文静, 赵雨川, 卓文基, 郑磊. 体外诱导对氨基水杨酸高浓度耐药结核分枝杆菌及其突变位点研究[J]. 中国防痨杂志, 2023, 45(1): 60-66. doi: 10.19982/j.issn.1000-6621.20220457

Yu Meiling, Zhang Chenchen, Wei Wenjing, Zhao Yuchuan, Zhuo Wenji, Zheng Lei. Study on high-concentration p-aminosalicylic acid resistant Mycobacterium tuberculosis induced in vitro and the mutation sites[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 60-66. doi: 10.19982/j.issn.1000-6621.20220457

图/表 3

图1

表1

诱导的耐PAS结核分枝杆菌对14种抗结核药物的交叉耐药性 (mg/L)

菌株	INH (MIC= 0.2)	Sm (MIC= 2)	EMB (MIC= 5)	Ofx (MIC= 2)	Mfx (MIC= 0.5)	Am (MIC= 1)	Km (MIC= 5)	Cm (MIC= 2)	Pto (MIC= 2.5)	PAS (MIC= 1)	RFP (MIC= 1)	Rfb (MIC= 0.5)	Lfx (MIC= 2)	PZA (MIC= 100)
P1	<0.025	0.50	1.25	0.5	0.12	1	2.50	1	<0.62	<0.5	<0.25	<0.12	<0.5	<50
P2	<0.025	0.50	1.25	1.0	0.12	1	2.50	1	<0.62	<0.5	<0.25	<0.12	<0.5	<50
P3	<0.025	<0.25	1.25	1.0	0.25	1	2.50	2	<0.62	4.0	0.50	<0.12	<0.5	<50
P4	0.200	0.50	1.25	1.0	0.12	1	1.25	1	<0.62	4.0	0.50	<0.12	<0.5	<50
P5	0.200	0.50	1.25	1.0	0.12	1	2.50	1	<0.62	4.0	0.50	<0.12	<0.5	<50
P6	<0.025	<0.25	1.25	1.0	0.12	1	2.50	2	<0.62	8.0	<0.25	<0.12	<0.5	<50
P7	<0.025	<0.25	1.25	1.0	0.25	1	2.50	2	<0.62	8.0	<0.25	<0.12	<0.5	<50
P8	<0.025	<0.25	1.25	1.0	0.12	1	2.50	2	<0.62	16.0	<0.25	<0.12	<0.5	<50
P9	<0.025	0.50	1.25	1.0	0.12	1	2.50	2	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P10	<0.025	<0.25	1.25	1.0	0.12	1	2.50	1	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P11	<0.025	<0.25	1.25	1.0	0.12	1	2.50	1	1.25	>16.0	<0.25	<0.12	<0.5	<50
P12	0.100	0.50	2.50	1.0	0.25	1	5.00	2	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P13	<0.025	<0.25	1.25	1.0	0.12	1	2.50	2	<0.62	16.0	0.50	<0.12	<0.5	<50
P14	0.050	0.50	1.25	1.0	0.12	1	2.50	2	<0.62	16.0	0.50	<0.12	<0.5	<50
P15	<0.025	0.50	1.25	1.0	0.12	1	2.50	2	<0.62	16.0	<0.25	<0.12	<0.5	<50
P16	<0.025	0.50	1.25	1.0	0.12	1	2.50	2	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P17	<0.025	0.50	1.25	1.0	0.12	1	2.50	2	1.25	>16.0	0.50	<0.12	<0.5	<50
P18	<0.025	0.50	1.25	1.0	0.12	1	2.50	2	<0.62	16.0	<0.25	<0.12	<0.5	<50
P19	0.050	<0.25	1.25	1.0	0.12	1	2.50	1	<0.62	16.0	<0.25	<0.12	<0.5	<50
P20	<0.025	<0.25	1.25	1.0	0.12	1	2.50	1	<0.62	16.0	<0.25	<0.12	<0.5	<50
P21	<0.025	<0.25	1.25	0.5	0.12	1	2.50	1	<0.62	16.0	<0.25	<0.12	<0.5	<50
P22	0.050	<0.25	1.25	1.0	0.12	1	2.50	2	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P23	0.050	0.50	1.25	1.0	0.12	1	2.50	2	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P24	<0.025	<0.25	1.25	1.0	0.12	1	2.50	1	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P25	<0.025	0.50	1.25	1.0	0.12	1	2.50	1	<0.62	>16.0	<0.25	<0.12	<0.5	<50
P26	0.050	<0.25	1.25	1.0	0.25	1	2.50	1	<0.62	>16.0	<0.25	<0.12	<0.5	<50

表1

表2

参考文献 19

[1]	World Health Oganization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[2]	Dookie N, Rmbaran S, Pdayatchi N, et al. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the mole-cular determinants of resistance and implications for personali-zed care. J Antimicrob Chemother, 2018, 73(5): 1138-1151. doi:10.1093/jac/dkx506. doi: 10.1093/jac/dkx506. URL
[3]	郑晓静, 杜博平, 贾红彦, 等. 结核分枝杆菌对氨基水杨酸耐药相关基因的筛选及鉴定. 北京医学, 2012, 34(9): 783-786. doi:CNKI:SUN:BJYX.0.2012-09-003. doi: CNKI:SUN:BJYX.0.2012-09-003.
[4]	Fivian-Hughes AS, Houghton J, Davis EO. Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology (Reading), 2012, 158(Pt 2): 308-318. doi:10.1099/mic.0.053983-0. doi: 10.1099/mic.0.053983-0. URL
[5]	Luo M, Li K, Zhang H, et al. Molecular characterization of para-aminosalicylic acid resistant Mycobacterium tuberculosis clinical isolates in southwestern China. Infect Drug Resist, 2019, 12:2269-2275. doi:10.2147/IDR.S207259s. doi: 10.2147/IDR.S207259s. URL
[6]	Zhao F, Wang XD, Erber LN, et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-amino-salicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(3): 1479-1487. doi:10.1128/AAC.01775-13. doi: 10.1128/AAC.01775-13 pmid: 24366731
[7]	Zhang X, Liu L, Zhang Y, et al. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012. Antimicrob Agents Chemother, 2015, 59(2): 1320-1324. doi:10.1128/AAC.03695-14. doi: 10.1128/AAC.03695-14 pmid: 25421465
[8]	Chakraborty S, Gruber T, Barry CE, et al. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science, 2013, 339(6115): 88-91. doi:10.1126/science.1228980. doi: 10.1126/science.1228980 pmid: 23118010
[9]	Zheng J, Rubin EJ, Bifant P, et al. Para-Aminosalicylic acid is a prodrug tReting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem, 2013, 288(32): 23447-23456. doi:10.1074/jbc.M113.475798. doi: 10.1074/jbc.M113.475798 pmid: 23779105
[10]	孟繁荣, 杨瑜, 雷杰, 等. 中国氟喹诺酮耐药结核分枝杆菌gyr基因序列特征分析. 实用医学杂志, 2020, 36(11): 1503-1508. doi:10.3969/j.issn.1006-5725.2020.11.019. doi: 10.3969/j.issn.1006-5725.2020.11.019.
[11]	戚应杰, 查晓丹. 耐多药结核分枝杆菌基因位点表达研究. 实用医学杂志, 2016, 32(24): 4118-4121. doi:10.3969/j.issn.1006-5725.2016.24.040. doi: 10.3969/j.issn.1006-5725.2016.24.040.
[12]	Barreral L, Cooreman E, de Dieu Iragena J, et al. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva: World Health Organization, 2008.
[13]	Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707): 223-227. doi:10.1126/science.1106753. doi: 10.1126/science.1106753. pmid: 15591164
[14]	Farhat MR, Freschi L, Calderon R, et al. GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. Nat Commun, 2019, 10(1): 2128. doi:10.1038/s41467-019-10110-6. doi: 10.1038/s41467-019-10110-6.
[15]	Coll F, Phelan J, Hill-Cawthorne GA, et al. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet, 2018, 50(2): 307-316. doi:10.1038/s41588-017-0029-0. doi: 10.1038/s41588-017-0029-0
[16]	Hicks ND, Yang J, Zhang X, et al. Clinically prevalent mutations in Mycobacterium tuberculosis alter propionate metabolism and mediate multidrug tolerance. Nat Microbiol, 2018, 3(9): 1032-1042. doi:10.1038/s41564-018-0218-3. doi: 10.1038/s41564-018-0218-3. URL
[17]	Satta G, Witney AA, Begum N, et al. Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of para-Aminosalicylic Acid and Its Resistance. Antimicrob Agents Chemother, 2020, 64(9): e00675-20. doi:10.1128/AAC.00675-20. doi: 10.1128/AAC.00675-20.
[18]	Li G, Zhang J, Jiang Y, et al. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resis-tant Mycobacterium tuberculosis isolates in China. J Glob Antimicrob Resist, 2020, 20:275-281. doi:10.1016/j.jgar.2019.08.005. doi: 10.1016/j.jgar.2019.08.005. URL
[19]	Sy SK, De Kock L, Diacon AH, et al. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother, 2015, 59(7): 4129-4138. doi:10.1128/AAC.04049-14. doi: 10.1128/AAC.04049-14 pmid: 25963985